CN107372609A - Apple virus disease vaccine - Google Patents
Apple virus disease vaccine Download PDFInfo
- Publication number
- CN107372609A CN107372609A CN201710626272.6A CN201710626272A CN107372609A CN 107372609 A CN107372609 A CN 107372609A CN 201710626272 A CN201710626272 A CN 201710626272A CN 107372609 A CN107372609 A CN 107372609A
- Authority
- CN
- China
- Prior art keywords
- apple
- phosphoric acid
- mother liquor
- virus
- disease vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pest Control & Pesticides (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A kind of Apple virus disease vaccine, it is characterized in that：Include ACLSV, ASGV virus strains, phosphoric acid, filter, mother liquor Sucrose, fruit amine.A kind of beneficial effect of Apple virus disease vaccine of the present invention is：Change conventional vaccine only has operation to bacterial disease, and for the helpless situation of virus, and it is non-pathogenic virus bacterial strain to grab composition, can breed sustained effectiveness for a long time, and uses injection system, and action faster becomes apparent from.
Description
Technical field
The invention belongs to a kind of apple vaccine.
Background technology
Existing apple vaccine, only the function with antibacterial, the disease triggered for more tiny virus are then incompetent
For power, given vaccine uses the preparation of various compounds, it is impossible to permanent effective.
The content of the invention
In order to solve the above problems, the present invention provides a kind of Apple virus disease vaccine, and just solving given vaccine can only
Bacterium class disease is acted on, and for the helpless situation of virus disease, this just compensate for given vaccine using simplification
Compound, it is impossible to the defects of working for a long time.
To achieve these goals, the technical solution adopted by the present invention is：A kind of Apple virus disease vaccine, it is characterized in that：
Include ACLSV, ASGV virus strains, phosphoric acid, filter, mother liquor Sucrose, fruit amine,
Wherein, described a kind of Apple virus disease vaccine infection observation algebraically：Ten generations；
Wherein, a kind of pH value of described Apple virus disease vaccine is 7
Wherein, the solution proportion virus strains and phosphorylated ligand ratio of a kind of described Apple virus disease vaccine：1:2；Phosphoric acid concentration：
0.08mol/L；Mother liquor sucrose fraction：8%；Mother liquor cytolysin fraction：4%；Fruit amine percentage：2%
A kind of beneficial effect of Apple virus disease vaccine of the present invention is：Change conventional vaccine only has operation to bacterial disease,
For the helpless situation of virus, and it is non-pathogenic virus bacterial strain to grab composition, can breed sustained effectiveness for a long time, and adopt
With injection system, action faster becomes apparent from.
A kind of preparation method of Apple virus disease vaccine, it is characterized in that：
Step 1, raw material A CLSV, ASGV virus strains, phosphoric acid, filter, mother liquor Sucrose, fruit amine are prepared
Step 2, by being activated after weak ospc gene is found, apple is infected, reproductive order of generation finds gene stabilization person after reaching for ten generations
Retain, then according to phosphoric acid with 1:2 proportioning is mixed, and phosphoric acid concentration 0.08mol/L, PH are 7 or so, control extraction
Time is 25min or so；
Step 3, then supernatant is removed by the way of centrifuging, the bacterium solution that then will be left behind is in 380KD with specification
Empty cortina filter is filtered, and concentration ratio reaches 25 times；
Step 4, by obtained concentrate be placed in percentage of sucrose, cytolysin percentage, fruit amine percentage account for 8% respectively,
Among 4% and 2% mother liquor, it is 18 hours or so to control incubation time；
Step 5, bacterium solution is freezed, it is below -20 degree to control cryogenic temperature, and at least three times, vaccine is made in freezing number.
Brief description of the drawings
Fig. 1 is a kind of flow chart of the preparation method of Apple virus disease vaccine.
Embodiment
To achieve the above object, a kind of technical scheme of Apple virus disease vaccine of the present invention is：
A kind of Apple virus disease vaccine, it is characterized in that：Include ACLSV, ASGV virus strains, phosphoric acid, filter, mother liquor sucrose
Divide, fruit amine.
Wherein, a kind of pH value of described Apple virus disease vaccine is 7
Wherein, the solution proportion virus strains and phosphorylated ligand ratio of a kind of described Apple virus disease vaccine：1:2；Phosphoric acid concentration：
0.08mol/L；Mother liquor sucrose fraction：8%；Mother liquor cytolysin fraction：4%；Fruit amine percentage：2%
A kind of preparation method of Apple virus disease vaccine, it is characterized in that：
Step 1, raw material A CLSV, ASGV virus strains, phosphoric acid, filter, mother liquor Sucrose, fruit amine are prepared
Step 2, by being activated after weak ospc gene is found, apple is infected, reproductive order of generation finds gene stabilization person after reaching for ten generations
Retain, then according to phosphoric acid with 1:2 proportioning is mixed, and phosphoric acid concentration 0.08mol/L, PH are 7 or so, control extraction
Time is 25min or so；
Step 3, then supernatant is removed by the way of centrifuging, the bacterium solution that then will be left behind is in 380KD with specification
Empty cortina filter is filtered, and concentration ratio reaches 25 times；
Step 4, by obtained concentrate be placed in percentage of sucrose, cytolysin percentage, fruit amine percentage account for 8% respectively,
Among 4% and 2% mother liquor, it is 18 hours or so to control incubation time；
Step 5, bacterium solution is freezed, it is below -20 degree to control cryogenic temperature, and at least three times, vaccine is made in freezing number.
Claims (4)
1. a kind of Apple virus disease vaccine, it is characterized in that：Include ACLSV, ASGV virus strains, phosphoric acid, filter, mother liquor sugarcane
Sugar, fruit amine.
A kind of 2. Apple virus disease vaccine according to claim 1, it is characterized in that pH value is 7.
A kind of 3. Apple virus disease vaccine according to claim 1, it is characterized in that solution proportion virus strains and phosphorylated ligand
Than：1:2；Phosphoric acid concentration：0.08mol/L；Mother liquor sucrose fraction：8%；Mother liquor cytolysin fraction：4%；Fruit amine percentage：2%.
4. a kind of preparation method of Apple virus disease vaccine, it is characterized in that：
Step 1, raw material A CLSV, ASGV virus strains, phosphoric acid, filter, mother liquor Sucrose, fruit amine are prepared
Step 2, by being activated after weak ospc gene is found, apple is infected, reproductive order of generation finds gene stabilization person after reaching for ten generations
Retain, then according to phosphoric acid with 1:2 proportioning is mixed, and phosphoric acid concentration 0.08mol/L, PH are 7 or so, control extraction
Time is 25min or so；
Step 3, then supernatant is removed by the way of centrifuging, the bacterium solution that then will be left behind is in 380KD with specification
Empty cortina filter is filtered, and concentration ratio reaches 25 times；
Step 4, by obtained concentrate be placed in percentage of sucrose, cytolysin percentage, fruit amine percentage account for 8% respectively,
Among 4% and 2% mother liquor, it is 18 hours or so to control incubation time；
Step 5, bacterium solution is freezed, it is below -20 degree to control cryogenic temperature, and at least three times, vaccine is made in freezing number.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710626272.6A CN107372609A (en) | 2017-07-27 | 2017-07-27 | Apple virus disease vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710626272.6A CN107372609A (en) | 2017-07-27 | 2017-07-27 | Apple virus disease vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107372609A true CN107372609A (en) | 2017-11-24 |
Family
ID=60341942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710626272.6A Pending CN107372609A (en) | 2017-07-27 | 2017-07-27 | Apple virus disease vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107372609A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210266A (en) * | 1997-09-03 | 1999-03-10 | 山东省果树研究所 | Inspection of hidden virus in apple |
| JP3613090B2 (en) * | 1999-09-10 | 2005-01-26 | 日本バイオロジカルズ株式会社 | Production of attenuated viruses |
| CN101115842A (en) * | 2005-01-28 | 2008-01-30 | 爱康遗传有限公司 | Production of antibodies in plants with plus-sense single-stranded viral RNA vectors |
| CN101842383A (en) * | 2007-06-07 | 2010-09-22 | 孟山都投资股份有限公司 | The novel plant virus of called after tomato wilt poison |
| CN102657169A (en) * | 2012-05-07 | 2012-09-12 | 江苏瑞光生物科技有限公司 | Use method of beta-1, 3 oligosaccharins plant disease-resistant vaccine |
| CN104673800A (en) * | 2015-03-20 | 2015-06-03 | 大连大学 | Method for preventing and treating fruit tree RNA virus |
-
2017
- 2017-07-27 CN CN201710626272.6A patent/CN107372609A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210266A (en) * | 1997-09-03 | 1999-03-10 | 山东省果树研究所 | Inspection of hidden virus in apple |
| JP3613090B2 (en) * | 1999-09-10 | 2005-01-26 | 日本バイオロジカルズ株式会社 | Production of attenuated viruses |
| CN101115842A (en) * | 2005-01-28 | 2008-01-30 | 爱康遗传有限公司 | Production of antibodies in plants with plus-sense single-stranded viral RNA vectors |
| CN101842383A (en) * | 2007-06-07 | 2010-09-22 | 孟山都投资股份有限公司 | The novel plant virus of called after tomato wilt poison |
| CN102657169A (en) * | 2012-05-07 | 2012-09-12 | 江苏瑞光生物科技有限公司 | Use method of beta-1, 3 oligosaccharins plant disease-resistant vaccine |
| CN104673800A (en) * | 2015-03-20 | 2015-06-03 | 大连大学 | Method for preventing and treating fruit tree RNA virus |
Non-Patent Citations (7)
| Title |
|---|
| 丘喜昭: "用低毒病毒防除植物病毒病", 《农业科技通讯》 * |
| 刘庆昌 等: "《植物细胞组织培养》", 31 January 2003, 中国农业大学出版社 * |
| 安德荣 等: "《植物病毒分类和鉴定的原理及方法》", 31 December 1995, 陕西科学技术出版社 * |
| 杜春梅: "《嘧肽霉素的开发与应用》", 31 March 2005, 黑龙江科学技术出版社 * |
| 罗明典: "病毒应用于农业的一些进展", 《病毒学杂志》 * |
| 陈国相1: "日本微生物农药研究、利用的进展", 《河北化工》 * |
| 齐秋锁: "利用弱病毒防治植物病毒病害的研究现状", 《河北农业大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102408462B (en) | Preparation method of erythromycin thiocyanate | |
| DK1866342T3 (en) | SEPARATION OF POLLUTANTS CONTAMINATING FROM STREPTOCOCCUS PNEUMONIAE POLYSACCHARID BY PH-MANIPULATION | |
| CN103160482B (en) | Method for preparing egg white lysozyme and active protein by adopting coseparation | |
| CN103432158B (en) | A kind of polysaccharide compound preventing and treating diarrhea of pigs and purposes | |
| CN111718410B (en) | Method for preparing yolk immunoglobulin | |
| JP2018538286A (en) | How to get saponin from plants | |
| TWI630241B (en) | Modulation method of phycocyanin | |
| Sebastião et al. | Composition of Extracellular Polymeric Substances (EPS) produced by Flavobacterium columnare isolated from tropical fish in Brazil | |
| CN103382462B (en) | A kind of Bacillus licheniformis N,O-Diacetylmuramidase and production method thereof and application | |
| JPH0341160B2 (en) | ||
| CN107372609A (en) | Apple virus disease vaccine | |
| CN104558156A (en) | Method for extracting human serum albumin from plasma and increasing yield | |
| CN204841021U (en) | Concentrated unit of poor cold extraction of high pressure | |
| CN104311628A (en) | Method for removing bacterial endotoxin in protein solution | |
| CN109321622A (en) | A kind of preparation method and its usage of Radix Notoginseng polypeptide | |
| CN1129609C (en) | Flocculation charification-ultrafiltration concentration process of producing composite immunoreactive protein | |
| CN104725503A (en) | Fugu rubripes nervous necrosis virus capsid protein egg yolk antibody and application thereof | |
| CN102526729A (en) | Preparation process of antitoxic serum for viral inactivation treatment | |
| CN107875377B (en) | Preparation method of clostridium perfringens type E toxoid vaccine | |
| CN105037579A (en) | Preparation process of crude polysaccharide of A-group Neisseria meningitidis bacterium capsule | |
| CN104628832A (en) | Method for purifying regrouped chicken colibacillosis outer membrane protein inclusion body and carrying out renaturation by utilizing high-efficiency renaturation liquid | |
| CN103665074A (en) | Extraction and purification method for natamycin in fermentation broth | |
| CN103571806A (en) | Method for rapidly separating and purifying dextran sucrase through two aqueous phase extraction | |
| CN102504042A (en) | Method for removing endotoxin from bacteria capsular polysaccharide | |
| CN101575374B (en) | Chicken Marek's virus antibody and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171124 |
|
| WD01 | Invention patent application deemed withdrawn after publication |